Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REL-1017 (Esmethadone) Long-Term Safety in Major Depressive Disorder
NCT04855760Phase 3Completed
- Sponsor
- Relmada Therapeutics, Inc.
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esmethadone in major depressive disorder (MDD), sponsored by Relmada Therapeutics, Inc.. Started Apr 2021; status: completed.
02
Drugs
esmethadone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04855760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855760.